Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Borgogna, Cinzia, Bruna, Riccardo, Griffante, Gloria, Martuscelli, Licia, De Andrea, Marco, Ferrante, Daniela, Patriarca, Andrea, Mahmoud, Abdurraouf Mokhtar, Gaidano, Valentina, Marchetti, Monia, Rapezzi, Davide, Lai, Michele, Pistello, Mauro, Ladetto, Marco, Massaia, Massimo, Gaidano, Gianluca, Gariglio, Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764505/
https://www.ncbi.nlm.nih.gov/pubmed/35042847
http://dx.doi.org/10.1038/s41408-022-00608-6
_version_ 1784634182156156928
author Borgogna, Cinzia
Bruna, Riccardo
Griffante, Gloria
Martuscelli, Licia
De Andrea, Marco
Ferrante, Daniela
Patriarca, Andrea
Mahmoud, Abdurraouf Mokhtar
Gaidano, Valentina
Marchetti, Monia
Rapezzi, Davide
Lai, Michele
Pistello, Mauro
Ladetto, Marco
Massaia, Massimo
Gaidano, Gianluca
Gariglio, Marisa
author_facet Borgogna, Cinzia
Bruna, Riccardo
Griffante, Gloria
Martuscelli, Licia
De Andrea, Marco
Ferrante, Daniela
Patriarca, Andrea
Mahmoud, Abdurraouf Mokhtar
Gaidano, Valentina
Marchetti, Monia
Rapezzi, Davide
Lai, Michele
Pistello, Mauro
Ladetto, Marco
Massaia, Massimo
Gaidano, Gianluca
Gariglio, Marisa
author_sort Borgogna, Cinzia
collection PubMed
description Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection.
format Online
Article
Text
id pubmed-8764505
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87645052022-01-18 Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients Borgogna, Cinzia Bruna, Riccardo Griffante, Gloria Martuscelli, Licia De Andrea, Marco Ferrante, Daniela Patriarca, Andrea Mahmoud, Abdurraouf Mokhtar Gaidano, Valentina Marchetti, Monia Rapezzi, Davide Lai, Michele Pistello, Mauro Ladetto, Marco Massaia, Massimo Gaidano, Gianluca Gariglio, Marisa Blood Cancer J Article Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection. Nature Publishing Group UK 2022-01-18 /pmc/articles/PMC8764505/ /pubmed/35042847 http://dx.doi.org/10.1038/s41408-022-00608-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Borgogna, Cinzia
Bruna, Riccardo
Griffante, Gloria
Martuscelli, Licia
De Andrea, Marco
Ferrante, Daniela
Patriarca, Andrea
Mahmoud, Abdurraouf Mokhtar
Gaidano, Valentina
Marchetti, Monia
Rapezzi, Davide
Lai, Michele
Pistello, Mauro
Ladetto, Marco
Massaia, Massimo
Gaidano, Gianluca
Gariglio, Marisa
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
title Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
title_full Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
title_fullStr Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
title_full_unstemmed Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
title_short Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
title_sort patterns of neutralizing humoral response to sars-cov-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764505/
https://www.ncbi.nlm.nih.gov/pubmed/35042847
http://dx.doi.org/10.1038/s41408-022-00608-6
work_keys_str_mv AT borgognacinzia patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT brunariccardo patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT griffantegloria patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT martuscellilicia patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT deandreamarco patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT ferrantedaniela patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT patriarcaandrea patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT mahmoudabdurraoufmokhtar patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT gaidanovalentina patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT marchettimonia patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT rapezzidavide patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT laimichele patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT pistellomauro patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT ladettomarco patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT massaiamassimo patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT gaidanogianluca patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients
AT garigliomarisa patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients